Publication

Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative

Liver International 40:2860-2876, 2020

Stokman G, van den Hoek AM, Thorbek DD, Pieterman EJ, Veidal SS, Basta B, Iruarrizaga-Lejarreta M, van der Hoorn JW, Verschuren L, Berbée JFP, Rensen PCN, Skjæret T, Alonso C, Feigh M, Kastelein JJP, Friedman SL, Princen HMG, Fraser DA

Subjects
Therapeutic AreaMouseCompoundob/ob mouseMethod/EndpointSpeciesAMLN ob/ob-NASH (AMLN ob/ob-MASH) mouseBody weightBlood biochemistryNon-alcoholic steatohepatitis/Metabolic dysfunction-associated steatohepatitis (NASH/MASH)Histopathology scoreImage analysisImmunohistochemistryLiver biopsyLiver morphometryIcosabutateObeticholic acid

Share this page

Resource Library

Related resources
Poster
A3907, a novel inhibitor of bile acid transport in the intestine and the kidney, improves markers of metabolic and hepatic pathology and reduces NAFLD activity score and fibrosis stage in a diet-induced and biopsy-confirmed mouse model of nonalcoholic steatohepatitis
Publication
Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis
Poster
Metabolic, biochemical, histological, and transcriptomic effects of semaglutide in the GAN diet-induced and biopsy-confirmed ob/ob mouse model of NASH
Publication
Multi-omics characterization of a diet-induced obese model of non-alcoholic steatohepatitis

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top